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Abstract
Background: Women with breast cancer want to participate in treatment decision-making. Guidelines have
confirmed the right of informed shared decision-making. However, previous research has shown that the
implementation of informed shared decision-making is suboptimal for reasons of limited resources of physicians,
power imbalances between patients and physicians and missing evidence-based patient information. We
developed an informed shared decision-making program for women with primary ductal carcinoma in situ (DCIS).
The program provides decision coaching for women by specialized nurses and aims at supporting involvement in
decision-making and informed choices.
In this trial, the informed shared decision-making program will be evaluated in breast care centers.
Methods/Design: A cluster randomized controlled trial will be conducted to compare the informed shared
decision-making program with standard care. The program comprises an evidence-based patient decision aid
and training of physicians (2 hours) and specialized breast care and oncology nurses (4 days) in informed
shared decision-making. Sixteen certified breast care centers will be included, with 192 women with primary
DCIS being recruited.
Primary outcome is the extent of patients’ involvement in shared decision-making as assessed by the
MAPPIN-Odyad (Multifocal approach to the ‘sharing’ in shared decision-making: observer instrument dyad).
Secondary endpoints include the sub-measures of the MAPPIN-inventory (MAPPIN-Onurse, MAPPIN-Ophysician,
MAPPIN-Opatient, MAPPIN-Qnurse, MAPPIN-Qpatient and MAPPIN-Qphysician), informed choice, decisional conflict
and the duration of encounters.
It is expected that decision coaching and the provision of evidence-based patient decision aids will increase
patients’ involvement in decision-making with informed choices and reduce decisional conflicts and duration
of physician encounters. Furthermore, an accompanying process evaluation will be conducted.
Discussion: To our knowledge, this is the first study investigating the implementation of decision coaches in
German breast care centers.
Trial registration: Current Controlled Trials ISRCTN46305518, date of registration: 5 June 2015.
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Background
Women with breast cancer want to participate in treat-
ment decision-making [1–3]. The German guideline rec-
ommends mastectomy or breast-conserving surgery
combined with (neo-) adjuvant treatments [4]. Benefits
and harms of treatments vary between options and differ-
ently impact patients’ physical and psychosocial quality of
life [5–7]. Therefore, women’s values and preferences are
essential. Treatment decisions should not be left exclu-
sively to the physicians [8].
So far, women’s preferences to participate have rarely
been considered in a structured manner [3]. This might
contribute to dissatisfaction with medical treatment de-
cisions [9]. The National Cancer Plan of the German
Ministry of Health and breast cancer treatment guide-
lines explicitly ask for patient participation in medical
decision-making [4, 6, 10, 11]. In addition, the German
patients’ right act clearly defines patients’ rights to
complete and unbiased information on benefits and
harms of all treatment options including the option not
to treat [12].
Evidence-based patient decision aids (ptDA) and the
consideration of women’s preferences are key issues in
decision-making [13]. Some women feel overloaded by
the plethora of information, usually given in a single
consultation [14]. The model of shared decision-making
(SDM) comprises evidence-based patient information
and weighing of pros and cons of treatment options
while taking women’s values and preferences into ac-
count. Barriers that might hamper the implementation
of informed SDM have been identified. They comprise
structural deficiencies in care settings, communication
or time issues [15, 16]. Patients experience discontinuity
in the process of care [14, 15] possibly due to a substan-
tial mismatch in knowledge, different role models or so-
cial and cultural backgrounds [2, 15]. Patients often do
not feel prepared to participate in decision-making due
to their limited knowledge. In SDM, acknowledgement
of patients’ preferences and values is as important as
knowledge about treatment options [17]. Even if women
decline to participate in decision-making, they often
wish detailed information about their disease and treat-
ment options [18, 19]. In case of declining, the decision
can be delegated to the health care team at any time.
SDM comprises the sharing of the decision-making
process, but not necessarily the sharing of the decision-
making itself [20]. Moreover, women have the right of
non-information.
State of research
Shared decision-making and decision coaching by specialized
breast care nurses
One opportunity to overcome some of these barriers is
the inter-professional model of informed shared decision-
making that facilitates patients’ involvement in treatment
decision-making [21].
Health care professionals support the decision-making
process as decision coaches, which may be defined as
“health professionals who provided information on
options and facilitated progress in decision making in
preparation for discussion with the practitioner who
would ultimately be responsible for making the decision
with the patient” [22].
The majority of projects on SDM have focused on the
education of the physicians [23–25]. Some studies have
shown that specialized nurses who acted as decision coa-
ches successfully enhanced patients’ decision-making
[22, 26–28]. Nurses have shown competences in explain-
ing medical information, supporting patients and sharing
the information with physicians [15]. At the Dartmouth-
Hitchcock-Medical-Center in New Hampshire, USA,
specially trained nurses and social workers prepare
patients for decision-making in a structured manner. A
consultation in the hospital’s “Center for Shared
Decision Making” is mandatory, for example, for breast
cancer patients who take part in the Comprehensive
Breast Program. This includes a pre-visit distribution of
decision aids into the standard care path and a continu-
ing care coordinator who guides patients through the
decision and care process [29, 30].
In Germany, nurses have already been involved in pa-
tient education in a structured manner within the scope
of the disease management programs for diabetes mellitus,
asthma and hypertension [2]. So far, neither the imple-
mentation of SDM [24, 31] nor SDM involving breast care
nurses or oncology nurses as decision coaches [22, 27] has
been implemented in oncology care settings. Specialized
nurses successfully completed at least an additional 1-
year training in care of breast cancer (oncology) pa-
tients [32–34]. SDM has not yet been included into the
curricula [33].
Effects of evidence-based patient decision aids on patient
participation in decision-making
Evidence-based patient information (EBPI) has fre-
quently been neglected in the scope of SDM. EBPI is a
prerequisite for informed SDM processes [35, 36]. The
combination of SDM and evidence-based ptDA enables
women to make informed choices defined by Marteau as
relevant knowledge about the treatment options and a
positive attitude congruent to their chosen treatment
[27, 37–39]. Previous research has shown that the exclu-
sive provision of written ptDA improves breast cancer pa-
tient’s knowledge and reduces decisional conflicts [40, 41].
However, the exclusive provision of evidence-based ptDA
for patients is not enough to enhance patient empower-
ment [42]. In Germany, strategies to improve evidence-
based patient participation have been explored, for
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example, within the care of multiple sclerosis patients.
Kasper et al. [42] evaluated an evidence-based ptDA on
immunotherapy in patients with multiple sclerosis. The
study could not show a difference in preference matches
between intervention and control group. Köpke et al.
showed that an interactive educational intervention
increased informed choices and slightly increased the
autonomy preference toward an active role in pa-
tients [43]. According to the Theory of Planned Be-
havior (TPB) autonomy preference only indicates
behavioral intention and not the behavior itself [44].
The TPB explains how peoples’ behavioral intentions
are influenced by social norms, their attitudes toward
the behavior and their perceived behavioral controls.
The behavioural intention is strongly associated with the
prediction of the behavior itself [44].
Collins et al. [41] reported that a decision aid on
breast cancer reduces decisional conflict in women fa-
cing a treatment decision on surgical options.
Within the scope of the German healthcare system,
evidence-based treatment and patient guidelines for
breast cancer have been developed [4]. However, these
guidelines do not provide adequate risk communication
on treatment options and especially harms. PtDA that
adequately consider criteria for EBPI are still rare within
the German healthcare system [45].
Evaluation of SDM
Measurements for SDM in inter-professional settings re-
main challenging. A variety of instruments exist to
measure preconditions, the SDM-process and outcome
parameters [46]. However, none of these instruments
focus on the inter-professional specifics of measuring
team processes and triangular SDM-processes among,
for example, doctors, nurses and patient.
Previous work
Development
We developed a program (decision coaching) to facilitate
informed SDM in oncology. The decision coaching will
be provided by specialized breast care or oncology
nurses combined with evidence-based ptDA. We address
women who are facing a primary treatment decision on
ductal carcinoma in situ (DCIS).
We chose DCIS, which is associated with a great ex-
tent of uncertainty. Women with DCIS have distinct in-
formation needs about the disease and its treatment
options [47]. Every year 6,500 women are diagnosed with
DCIS in Germany. The number of cases has been in-
creasing since the introduction of the national mam-
mography screening program [48]. Without screening,
DCIS is rarely diagnosed. Due to its symptomless nature,
it usually is an incidental finding. Approximately, 20 % of
the malignancies detected by screening are DCIS [49, 50].
DCIS is limited to the mammary ducts and associated
with an increased risk of invasive breast cancer. The
prognosis is unknown, but not all DCIS will progress
to invasive breast cancer [51]. Treatment is usually
recommended for all woman with DCIS because it is
impossible to predict which DCIS will develop into
invasive breast cancer [4].
We developed our program following the UK Medical
Research Council’s (MRC) guidance for the development
and evaluation of complex interventions [52] and ap-
plied the Theory of Planned Behavior. Our program
comprises an evidence-based ptDA [53], a curriculum
for specialized nurses and a workshop for physicians
[53, 54]. We developed our curricula according to the
six-step approach for the development of curricula in
medical education [55]. The evidence-based ptDA for
the primary treatment decision on DCIS has been de-
veloped according to the criteria for EBPI [38].
Pilot trial
Each component of the intervention was separately
piloted [54]. Finally, feasibility and acceptability of the
complete program has been evaluated in a phase II
study [53].
Two breast care centers (four nurses and five physi-
cians) in Berlin, Germany, recruited up to 6 patients
with DCIS [53]. All encounters with patients and nurses
were videotaped and analyzed. In sum, the study showed
that the program is feasible and acceptable. However, we
also identified barriers. The physician workshop revealed
the physicians’ desire to discuss treatment options; in
standard care, usually only the recommendation of the
tumor board is communicated to the patient, which is in
line with medical guidelines. This option is often seen as
the only possible treatment. Therefore, an open decision-
making process is inhibited. Physicians also unveiled
patients’ supposed expectation of doctors. According
to their opinions, patients expect clear treatment rec-
ommendations. Both professional groups - nurses and
physicians - pointed out that it is not necessary to ask
patients for their preferences because they already
know which option would be the best for the patients.
Although each woman fulfilling the inclusion criteria
should have been asked for study participation, not all
women were asked for participation because physicians
were concerned that some women might be overbur-
dened by SDM due to age or educational background.
Another barrier consists in the predefined number of
specific surgical procedures that lead to a doubtful
incentive for breast care centers. Physicians were con-
cerned about offering women all treatment options
since they had to justify their treatment to the certifi-
cation body that defines the quality indicators.
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We address the potential barriers in our educational
intervention by discussing the possible impact of per-
sonal attitudes and giving advice on how to communi-
cate the recommendation of the tumor board. In
addition, we developed supplementary material such as
prompt cards and fact sheets to structure the decision
coaching sessions.
Objectives
This study aims to assess efficacy of the decision coach-
ing program. The key hypothesis is that women who re-
ceive an evidence-based ptDA and decision coaching by
specially trained breast care or oncology nurses are more
involved in decision-making compared to standard care.
We also hypothesize that women in the intervention
group will make more informed choices based on their
preferences and values.
Further objectives are to assess if women’s decisional
conflicts will decrease and if the duration of physician
encounters will be shortened.
Alongside the trial, the processes, facilitators and bar-
riers to implementation will be qualitatively assessed.
Methods/Design
This protocol is reported following the criteria of the
standard protocol items: recommendations for interven-
tional trials (SPIRIT) [56] and the MRC-Framework for
the development and evaluation of complex interven-
tions [52]. For the completed SPIRIT checklist see
Additional file 1.
Trial design
The intervention will affect the structures and proce-
dures of the breast care centers. To avoid contamination,
allocation will be carried out on the level of the breast
care centers rather than the individual patient [57]. The
trial is designed as a superiority cluster randomized
controlled trial with a parallel group design and 1:1
allocation ratio.
Study setting
The study will be conducted in certified breast care cen-
ters. Breast care centers in Germany in the federal states
of Schleswig-Holstein, Hamburg, Bremen, North Rhine-
Westphalia, Hessen, Saxony-Anhalt, Mecklenburg-West
Pomerania and Lower Saxony will be invited for partici-
pation by sending an email with brief information and
personal contact details. Usually, breast cancer patients
are referred to breast care centers to verify diagnosis and
provide treatment. Certified centers offer quality as-
sured care based on evidence-based medical treatment
guidelines [10, 11]. That implies that breast care cen-
ters have to treat a predefined number of patients per
year. The diagnoses and treatment recommendations
have to be made by a multi-professional healthcare
team. Usually, the tumor board’s treatment recom-
mendation is made prior to the primary treatment of
DCIS and before talking with patients about treatment op-
tions. In most breast care centers, patients are only offered
this treatment recommendation. Breast care centers are
continuously evaluated, using predefined quality indica-
tors [58, 59]. Certification guidelines require the involve-
ment of breast care nurses or oncology nurses in patient
care. In sum, certification allows comparability of the par-
ticipating centers.
Eligibility criteria
Breast care centers are eligible if they have been certified
according to a German or European certification body
(such as Onkozert, Äkzert or EUSOMA). Breast care cen-
ters have to agree to release the specialized nurses from
duty to allow participation in physician consultations and
tumor boards and to conduct decision coaching sessions.
Physicians have to be dispensed for the workshop.
Nurses are eligible if they have a 1- or 2-year advanced
training as breast care nurses or oncology nurses or if
they have been entrusted with breast care nurses’ tasks
for at least 6 months.
Physicians are eligible if they are involved in the infor-
mation process of women facing a primary treatment
decision on DCIS.
Women aged 18 years or older with a primary, histo-
logically confirmed DCIS in the absence of invasive
breast or lobular carcinoma in situ and facing a primary
treatment decision will fulfil the inclusion criteria. Since
all the information is provided in the German language,
patients need sufficient language skills.
Written informed consent will be obtained from physi-
cians, nurses and women.
Patient exclusion criteria
Women who are pregnant, have a known BRCA 1/2 mu-
tation or who had a previous diagnosis of breast cancer
or DCIS (irrespective if ipsi- or contralateral) are not eli-
gible. Furthermore, women with contraindications for
radiotherapy will not be included. Women seeking a sec-
ond opinion will be excluded to avoid contamination of
the study arms since participating women are allowed to
consult a further breast care center for a second opinion.
Interventions
Intervention clusters
Nurse training The nurse training lasts 4 days and
comprises two modules. The modules contain basics of
evidence-based medicine and EBPI including risk
communication, an introduction into the developed
evidence-based ptDA for women with DCIS and a struc-
tured training in SDM [53]. In addition to lectures and
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presentations, role plays are used to acquire decision
coaching skills. Prompt cards, a patient decision guid-
ance and fact sheets will be used to structure decision
coaching sessions and ensure that coaching is delivered
as intended. Decision coaches will receive a folder com-
prising the educational material with additional litera-
ture. The nurse training will be delivered near the
nurses’ workplaces. The group size will not exceed eight
participants. The training success will be surveyed using
exercises and knowledge tests, which will be analyzed
and discussed with participants. The decision coaches
receive a structured feedback for the first two decision
coaching sessions with women in their centers.
Physician workshop The workshop for physicians lasts
2 hours. It provides an overview of the SDM concept
and delivers basics concerning relative and absolute risk
reduction. The possible treatment options and its evi-
dences are discussed. Furthermore, participants receive a
workshop manual, the evidence-based ptDA and gain
insight into the decision coaching sessions. In sum, the
physicians get the information that their patients will be
given before their consultation and are instructed on
their role within this process. The workshop will be de-
livered in each breast care center randomized to the
intervention group (IG). The number of workshop par-
ticipants is not restricted.
All trainings and workshops will be conducted by re-
searchers of the University of Hamburg (BBH, KL
and ASt) MIN-Faculty, Unit of Health Sciences and
Education.
Evidence based ptDA The ptDA contains evidence-
based information on DCIS, the natural course of the
disease, and treatment options including benefits and
harms. Due to the paucity of randomized controlled
trials, the uncertainties about harms and benefits of
treatment options remain high. Existing randomized
controlled trials insufficiently report the harms of treat-
ments [53]. We also included the option “watchful wait-
ing” in our ptDA although we have no credible data and
predictors to estimate how often and under which con-
ditions an invasive breast cancer will develop. We there-
fore communicate the risks that come along with this
procedure in detail. Data on frequencies will not be
available until the results of the ongoing LORIS-trial will
be published. This RCT has recently started and com-
pares active monitoring with surgery. It will provide at
least some answers [60].
Patients Women are offered a decision-making process
supported by an evidence-based ptDA, at least one
decision coaching session with a trained nurse and a
final physician encounter (see Fig. 1).
Nurses will provide information on the decision
coaching, the evidence-based ptDA and the decision
guidance that is targeted to the decision to be made.
They will also arrange a new appointment within 1 week
for the decision coaching and provide her contact de-
tails. At the next appointment, the nurse supports the
woman’s decision-making process in a structured man-
ner, considering the six steps of SDM [61, 62]:
1. Definition of the problem requiring a decision-
making process
2. Key message (There is more than one option, and
the best option depends on how the patients value
the evidence, the benefits and harms considering
their expectations and preferences.)
3. Information about the options, including benefits
and harms based on EBPI
4. Clarifying patient’s values and preferences
5. Decision-making (optional to postpone the decision)
6. Arrangement
Nurses will carry out the first five steps. If the woman
is not ready to make a decision yet, an additional deci-
sion coaching session will be offered. If the woman
makes her decision, the nurse will arrange the physician
consultation in which physician and woman discuss the
preferred option and talk about remaining questions.
Patients and physicians will make an arrangement about
treatment or watchful waiting (sixth SDM-step) and pos-
sibilities to evaluate the decision. Women are allowed to
revise their decision at any time if they are not satisfied
with their initial decision.
Control cluster
In the control cluster, standard care will be delivered.
Women will not receive any additional information or
counselling on treatment options other than that usually
provided by breast care centers. In general, standard care
comprises one or two physician encounters in which the
women are informed about their diagnosis and the treat-
ment recommendation of the tumor board and their in-
formed consent for treatment is obtained. Standard care
procedures of each breast care center will be assessed at
the beginning of the study. We expect centers to be
comparable due to certification guidelines.
Criteria for discontinuation
Adverse events
We do not expect adverse effects caused by decision
coaching. However, uncertainty of treatment options for
DCIS is high. The natural course of the disease is un-
known [51, 63]. Since it is impossible to predict which
DCIS develops into invasive breast cancer, medical treat-
ment guidelines recommend that all women with DCIS
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Fig. 1 Participant timeline
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should be treated. In principle, every woman has the
right to decline treatment. In our pilot study, physicians
and nurses reported on women who have chosen this
option, which often resulted in high social pressure by
healthcare professionals and relatives. As a result,
women may refuse further surveillance for fear of being
rejected by physicians.
Uncertainties related to treatment options might
frighten women. On the other hand, the entire informa-
tion including pros and cons and nurses’ guidance
through the decision-making process could decrease un-
certainty in women [64].
We do not expect harm. In addition, psycho-
oncological support has been implemented into stand-
ard care. Women will also be informed about this
proposition in the study information sheet. Before-
hand, the psycho-oncologist will be informed about
the study.
Participant withdrawal
All participants will receive written and verbal infor-
mation about their opportunity to withdraw from the
study at any time without any consequences, and in
that event, the participant’s data will be deleted. Par-
ticipant withdrawal is possible under specification of
the participant’s code number. A withdrawal of anon-
ymized data is not possible.
Baseline data
The following data will be surveyed from breast care
centers before randomization: Primary cases of DCIS
treated with (1) breast-conserving therapy, (2) additional
recommendation of radiotherapy afterwards and (3)
mastectomy in 2014, certification body (Onkozert,
EUSOMA, ÄKzert), number of specialized nurses in the
breast care centers, number of treating physicians and
procedures in the breast care center.
Baseline characteristics of specialized nurses include age,
gender, working experience, training and education, job
specification, knowledge about DCIS, experiences in
patient counselling, participation in physician consultations
and tumor boards and nurses’ understanding of their role.
Baseline characteristics of physicians include age, gen-
der, working experience in senology, qualification, atti-
tude towards the inter-professional collaboration and
knowledge about evidence-based medicine and SDM.
Baseline characteristics of women with DCIS include
age, educational level, disease and diagnostic parameters
(size of DCIS, histologic type = grading, architecture,
focality, hormone-/HER2-receptor-status if available,
comorbidities, mode of detection) (all diagnostic param-
eters will be extracted from the patient record), informa-
tion about health information behavior, and advance
information about DCIS.
All baseline characteristics except for the women will
be assessed before randomization to avoid bias.
Outcomes
Primary outcome: MAPPIN-Odyad
Different outcomes have been discussed. For the evalu-
ation of our main hypothesis, we will use the observer
instrument “Multifocal APProach to the sharing IN
Shared Decision-making” (MAPPIN’SDM) [23]. As an
instrument for the assessment of the primary outcome
the observer-based instrument MAPPIN-Odyad of the
MAPPIN-inventory will be applied. It assesses the mu-
tual SDM behavior of physicians and patients based on
video recordings.
Informed choice would have been a suitable endpoint,
too. The intervention addresses the enhancement of pa-
tient participation, which is part of SDM. The estimation
of patient participation requires an analysis of the
decision-making process and its communicative details.
Informed choice is an outcome measure, which corre-
lates with patient participation, but it is not congruent.
Therefore, the process itself is the primary endpoint of
the study, and further outcome variables have been de-
fined as secondary endpoints. A list of all outcomes is
provided in Table 1.
MAPPIN-Odyad is one part of the MAPPIN’SDM in-
ventory that enables the appraisal of medical decision
communication with three perspectives: physician, pa-
tient and observer. The aim of the instrument is to as-
sess the extent of patient participation. All three
perspectives consist of the same SDM criteria contained
in analogous items. The relevant evaluation unit is the
dyad of physician and patient. Physician and patient as-
sess how they perceived the mutual SDM process. The
observer rates the SDM behavior of the physician and
patient and of the interaction of the dyad (physician and
patient) based on video recordings.
The multifocal approach with dyad as evaluation
unit is unique for SDM process assessment inventor-
ies. Other instruments either skip at least one per-
spective (for example, SDM-Q) [65, 66] or focus the
action of only one conversational partner, mostly the
physician (for example, dyadic OPTION, OPTION 5)
[67–69]. In fact, a triangular measurement of SDM
including the whole decision-making process and all
participants (physician, nurse and patient) would be
desirable. However, such instruments do not exist
[46]. Originally, MAPPIN’SDM has been developed to
assess the communication between physician and pa-
tient. Meanwhile an adapted version for the decision
talk between health care professionals and patients
has been published [70]. Therefore the observer-based
MAPPIN’SDM-inventory (MAPPIN-Odyad) considering
the interaction of the patient with both, the physician
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and the nurse, will give a holistic view of the SDM
process (see below). The decision-making process in
the IG comprises the decision coaching by the nurse
and the patient-physician consultations. In the control
group (CG), the decision-making process comprises
the patient-physician consultations.
The revised version of the instrument (MAPPIN’SDM-
revised) is available, comprising a set of nine SDM indica-
tors per perspective, which cover the international
consensus of the essential SDM competencies [71].
Both MAPPIN’SDM questionnaires (healthcare pro-
vider and patient) and the observer instrument comprise
11 items (one indicator has three components). Six indi-
cators outline the chronological order of an SDM talk.
Three indicators contain meta-communicative compo-
nents. All indicators are assessed on a five-point-scale
from 0 to 4 (for example, observer instrument: ‘compe-
tence was not observed’ to ‘excellent performance’).
For the primary outcome in the IG, two trained
raters will independently rate MAPPIN’SDMdyad for
the whole decision-making process, consisting of two
talks (nurse-patient and physician-patient). In a sec-
ond step, they build a consensus. In the last step, we
will calculate mean values of the final scores for the
primary endpoint.
In the CG, the decision-making process is limited to the
patient-physician consultations. The rating procedure is
identical to the IG, but the decision-making process com-
prises only one consultation (physician-patient).
Test quality of an observer-instrument consists of sev-
eral data. The typical item parameters as well as the reli-
ability of the questionnaire are adequate (mean item
difficulty = 1.51 (SD = 0.76), mean corrected item total
correlation = 0.53 (SD = 0.19), Cronbachs alpha = 0.84).
The reliability and validity of the observer data are rele-
vant as well. Previous research has shown adequate
interrater-reliability (mean T = 0.45). Validity calcula-
tions were conducted by sensitivity and specificity meas-
urement in comparison to one SDM-expert. High
validity values were reached (mean sensitivity = 0.67,
mean specificity = 0.81) [72].
Secondary outcomes
MAPPIN-Q(patient/nurse/physician) To take patients’ and
health care professionals’ perspective of SDM into
account, the remaining components of the MAP-
PIN’SDM-inventory will be used. This comprises
women-, nurse- and physician-based judgments about
their perceptions of the mutual decision-making
process (MAPPIN-Qpatient, MAPPIN-Qnurse and
MAPPIN-Qphysician, respectively). The healthcare pro-
fessionals will be familiar with the questionnaire be-
cause they fill in the questionnaire for every woman.
Table 1 Outcome parameters
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Patients in the IG fill in the questionnaire two times
(talk with nurse, talk with physician), and patients in
the CG fill in the questionnaire once.
The concordance between SDM judgment of patient
and physician/nurse by a nonparametric concordance
measure will be calculated (weighted T (MAPPIN-
Qpatient and MAPPIN-Qphysician) and weighted T
(MAPPIN-Qpatient and MAPPIN-Qnurse)).
MAPPIN-Odyad of the decision coaching sessions and
MAPPIN-Odyad of the physician encounter will be re-
ported separately, as well as the observer ratings of pa-
tients and healthcare professionals (MAPPIN-Opatient,
MAPPIN-Onurse and MAPPIN-Ophysician).
Every part of the MAPPIN’SDM-inventory has 11
items and answer format of a graduated Likert scale
from 0 to 4 (see primary outcome). The test values per
person are calculated by the mean of the 11 item an-
swers. All MAPPIN’SDM-ratings and -questionnaires
that are applied for secondary outcomes have similar test
quality as the primary outcome [73].
Informed choice Following up Marteau’s definition of
informed choice, the measure of this construct com-
bines three dichotomous dimensions: (a) risk know-
ledge, (b) attitude and (c) uptake [37]. These three
dimensions will be connected to one dichotomous
outcome. Informed choice can be obtained if women
have adequate risk knowledge of the treatment op-
tions, and their uptake of one treatment option is
congruent with their positive attitude for the chosen
option (see Table 2) [37].
The single dimensions of the instrument are described
below:
a) Risk knowledge
A 12-item knowledge test has been developed to
measure risk knowledge. The test includes questions
on diagnosis and prognosis of DCIS and benefits and
harms of available treatment options in multiple-
choice format. It was pretested in the pilot trial.
However, it cannot be considered a validated scale.
The score is calculated by the sum of correct
answers (maximum value 12). Total values will be
dichotomized in adequate risk knowledge (at least
75 %; ≥ 8 correct answers) and non-adequate
knowledge (<8 correct answers). If patients fill in at
least one item of the risk knowledge test, unanswered
questions will be rated as incorrect. If none of the
questions is answered, the test will be classified as
missing data. All patients will fill in the risk knowledge
test after their last physician encounter to avoid
questions from patients triggered from the test items.
b) Attitude
The attitude of patients toward the options will be
assessed during the SDM process. Because the
decision can be influenced by several factors, the
attitude in the IG will be assessed at baseline, before
the first decision coaching session (after reading the
decision aid), after the last decision coaching session
and after the final physician encounter in which the
treatment decision is made. In the CG, attitude will
be assessed before (baseline) and after the physician
encounter. The questionnaire comprises the attitude
for every option using a four-point Likert scale
(“non-sensible” to “sensible”). We will only include
the score regarding the treatment option that was
finally chosen by patients in the measure of
informed choice. The further judgments will be
assessed in the scope of the process evaluation.
The scale is newly developed.
c) Uptake
Uptake indicates whether women stick to their
decisions made with the medical team (nurses and
physicians) within the decision-making process. This
information will be extracted from patient records
2 months after the final physician encounter and is
included in the measure of informed choice.
To get a dichotomous value for informed choice, we
classify women with adequate knowledge and positive
attitude toward the chosen option as making an in-
formed choice. Additionally, all sub-dimensions of in-
formed choice (uptake, risk knowledge and attitude) will
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be analyzed separately. It is possible that diagnosis
changes after the decision-making process, for example,
if an invasive cancer is detected post-surgery. This
changes the preconditions for the treatment decision as
well. In such case, the initially favored treatment option
(for example, to dispense with radiotherapy) will not be
classified as uninformed; instead, the decision will be
rated only if the preconditions for the treatment decision
(= DCIS) did not change.
Decisional conflict Decisional conflict of patients will
be measured using the decisional conflict scale
(DCS). Decisional conflict is a condition in which
uncertainty about the right decision exists [74]. The
DCS includes five subscales: personal uncertainty,
modifiable deficits of feeling uninformed, unclear
values, inadequate support and perception that an in-
effective choice had been made. Sixteen items are
scored on a five-point Likert scale (1 = strongly agree
to 5 = strongly disagree).
A patient and physician version is available containing
the same items (dyadic DCS) [75]. In this study the
dyadic version is used and will be supplemented with a
nurse version. A German version of the DCS has been
validated with 1,286 patients and yielded good test qual-
ity [76]. Due to some imprecise item wordings, an
adapted physician version will be used that has recently
been developed and validated by Kasper et al. but has
not been published yet [77, 78].
Further parameters
Duration of consultations We will assess the duration
of decision coaching sessions and physician encounters
and the interval between the encounters.
In addition, data from all participants will be collected
during the accompanying process evaluation.
Procedures and data collection
Identification of eligible patients
Potentially eligible women will be identified during
the tumor boards or by upcoming appointments. To
avoid selection bias, an independent person will con-
tact participating breast care centers (specialized
nurses) weekly after the tumor boards to identify eli-
gible patients. Nurses will be instructed to alert physi-
cians of eligible patients. The number of primary
cases within the study period will be compared to the
number of patients identified as eligible and asked to
participate. Physicians of the participating breast care
centers will fill in a recruitment form. If inclusion cri-
teria are met, women will be invited to participate in
the study, and their informed consent will be ob-
tained (see Fig. 1). To avoid recruitment bias, physi-
cians receive a guideline to invite women with DCIS
in a standardized manner. Reasons to decline study
participation will be documented if unveiled.
Baseline data and allocation
Women in the IG will fill in the baseline data and atti-
tude toward treatment. Completion of questionnaires
will require 5 min. Afterward, women receive the DCIS-
ptDA and the patient decision guidance.
For women in the CG, the physician encounter will be
interrupted and women are invited to fill in baseline data
forms. Women are given enough time to think about
study participation. If they decide to participate, the
patient-physician encounter will continue according to
the study protocol.
Encounters one and two
Multiple assessments of the decisional conflict scale and
the MAPPIN-Qpatient can influence the results. Similar
preconditions between professionals and women, as well
as between the IG and CG, may avoid this bias. There-
fore, women receive these questionnaires for reading be-
fore the encounters with nurses and physicians. Before
the coaching session (and after reading of the ptDA), the
patient’s attitude toward treatment options will be
assessed again. The reading and completion of question-
naires will require 5 min. After the last decision coach-
ing session, patients in the IG will complete the
MAPPIN-Qpatient, the DCS and the attitude scale. Com-
pletion will require about 10 min.
Patients in the IG will complete the remaining question-
naires, including the risk knowledge test after the final
physician encounter, which requires about 15 min.
In the CG, patients will complete MAPPIN-Qpatient,
the attitude towards decision questionnaire, the DCS
and the risk knowledge questionnaire after finishing the
physician encounter (15 min).
After the final encounter with patients, nurses in the
IG and physicians in IG and CG will fill in the
MAPPIN-Qphysician/nurse and the DCS, respectively
(5 min).
Women will complete all questionnaires during their
appointments in the breast care centers to ensure com-
pleteness. If necessary, women will be provided with a
prepaid envelope.
If women do not complete all forms, they will be con-
tacted by the study nurse via telephone. Women will be
asked to fill in the forms at their next appointment. If
the decision-making process was already completed,
missing forms will be send to the woman by post.
We do not expect women to miss an appointment be-
cause often women feel time pressure for decision-
making due to the threatening diagnosis. Women would
be contacted by decision coaches to arrange a new ap-
pointment if they missed one.
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All encounters will be video recorded by nurses and phy-
sicians. The video camera will not focus on patients but on
the desk with the coaching material. The recordings will be
rated independently with the MAPPIN-Odyadby two raters.
Discrepancies will be solved by discussion after finishing
the rating respectively.
The final choice of women will be assessed 2 months
after the treatment decision was made.
Sample size
The sample size calculation is adapted to the primary
outcome (MAPPIN-Odyad) and is conducted under the
assumption of the same variances in both groups for a
continuous normally distributed target variable of a two-
arm cluster randomized controlled trial.
The assumption on the expected difference between
IG and KG and the possible size of the cluster effect is
based on previous research [77, 79–81]. A difference of
0.25 in the primary outcome should be revealed between
the groups with a power of 90 % and an assumed stand-
ard deviation of 0.4. Because we could not identify reli-
able estimates of the intracluster correlation coefficient
(ICCC), we estimate an intracluster correlation coeffi-
cient of 0.02 based on previous studies in stroke units
and hospitals and due to the fact that breast care centers
feature a high standardized care process through the cer-
tification [79, 80]. The cluster size will be m = 12 (12 pa-
tients per breast care center). As a primary test, a
cluster-adjusted t-test according to Donner et al. [82]
will be used. The calculation results in a sample size of
14 breast care centers with 168 patients based on an
alpha of 0.05. Under consideration of drop-outs, 16
breast care centers will be recruited with a total sample
size of n = 192 patients.
Recruitment
Breast care centers that have at least 20 primary cases of
DCIS per year will be invited for study participation. Breast
care centers and potential participating health care profes-
sionals will be informed about the study. Each breast care
center will recruit 12 patients within 9 months.
The recruitment of women will be conducted by the
physicians of the breast care centers.
Allocation
The statistician (BH) has provided a computer-generated
allocation sequence. A random permuted block design
using blocks of sizes 4, 6 or 8 will be used. No stratifica-
tion is performed. An independent external person will
unveil the allocation after inclusion of all breast care
centers. Corresponding to the cluster design, breast care
centers will be aware of their allocation status. To avoid
selection bias, patients will not receive information
about their allocation status. Women will be asked to
assume which kind of counselling procedure they re-
ceived because the unveiling of allocation could have in-
fluenced their responses.
If patients would have information about their allo-
cation status before participation, they might not
agree to participate or a nocebo-effect might occur in
the CG due to the assumption that their treatment
might be inferior to the IG. As opposed to this, pa-
tients in the intervention group might not agree since
they estimate for example, the expenditure of time
too high or they would insist on immediate treatment
decisions by physicians.
Blinding
Clusters and patients cannot be blinded (see above). Due
to the obviousness of the material used in the IG (for ex-
ample, prompt cards, decision guidance and fact sheets),
video raters cannot be blinded. However, the members
of the research team who enter the data are blinded to
allocation. The analyst will conduct a blinded review of
data before the study groups are unveiled, and the final
statistical analysis will be conducted.
Data management
Data will be administered and entered by the team
members of the Unit of Health Sciences and Education
of the University of Hamburg. Each study participant
will receive a pseudonym to allow for combining of data
sets of different time points. Data entry will be verified
by two blinded members of the research team. Data will
be stored for 10 years as suggested by the German
Research Foundation (DFG) [83].
Statistical methods
Statistical methods for analysing primary and
secondary outcomes
Data analysis will be conducted following the intention-
to-treat principle.
The patient participation (MAPPIN’SDM) in the deci-
sion process will be estimated by the primary outcome.
Mean values and cluster-adjusted standard deviation
[82] in IG and CG will be estimated and compared with
a cluster-adjusted t-test. Cluster adjustment is performed
using the intracluster correlation coefficient as described
in detail by Donner et al. [82]. Linear mixed models in-
cluding clusters as random effect would be an alternative
model [82]. Using a simple design, as in this trial, similar
results would be expected for both methods [82]. We
decided to use the simpler method of a cluster-adjusted
t-test, which has been used in many other cluster ran-
domized controlled trials before.
For all further MAPPIN-questionnaires (secondary
outcome) and ratings (inclusively concordance), cluster-
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adjusted t-tests are also used under the same assumption
as described before.
Sub-analysis will be conducted for physician and nurse
encounters separately for example, if some of the indica-
tors of MAPPIN could be observed more frequently in
nurse or in physician encounters.
Likelihoods of informed choices will be estimated by
cluster-adjusted confidence intervals and compared by a
cluster-adjusted chi-square-test [82].
Additionally, as secondary analysis, the risk know-
ledge will be compared nonparametrically between the
IG and CG by a Wilcoxon-test on cluster-level (as a
non-dichotomized measure).
As secondary analysis decisional conflict (DCS) will be
compared by a cluster-adjusted t-test.
All tests will be carried out two-tailed with a signifi-
cance level of α = 0.05, confidence intervals will be cal-
culated as two-tailed 95 % confidence intervals.
Methods for any additional analyses
Baseline data of both groups will be analyzed descrip-
tively. To ensure test quality, the used instruments will
be checked by item analysis that is oriented on the com-
mon parameters in literature [84].
Furthermore, it will be assessed descriptively, whether
women in the IG choose less invasive treatments more
often compared to women in the CG.
Handling of missing data
Only a few missing values of indicators are expected
for the primary outcome because the video rating by
the trained observers is very dependable. Missing
values are only expected if physicians or nurses start
the video too late or stop it too early, thereby missing
important information discussed with patients. In
those cases of missing values, the total score will be
calculated as a mean of the remaining ratings of the
video material. Otherwise, missing values will be im-
puted as described below.
Physicians or decision coaches might not record their
encounter with patients so that no video material for
analysis will be available. If no part of the decision-
making process has been recorded, the overall mean
score values of MAPPIN-Odyad will be imputed in the
calculation of the primary endpoint. It is expected that
only very few cases of imputation will occur (maximum
of about 5 % in each group). A secondary sensitivity ana-
lyses will be performed after excluding patients with im-
puted values of the primary outcome.
Secondary outcomes will be analyzed with a complete
case analysis. Questionnaires exceeding 20 % of missing
values will be excluded from analysis [85]. Based on former
studies, missing values should not be expected [78].
Monitoring
For the individual woman, the study period will be
2 months. We do not expect adverse events. Hence,
no safety board will be established, no interim ana-
lyses will be conducted, no stopping rules are defined,
and no audits have been planned in advance.
Strategies to improve study adherence and
intervention fidelity
After study centers have included two patients, study
centers (CG and IG) will be visited by one member of
the research team to ensure that study procedures (form
completion and video recordings of the encounters) are
conducted as intended.
Research ethics approval
Ethical clearance for the study has been obtained from
the ethical committee of the German Society of Nursing
Science (Deutsche Gesellschaft für Pflegewissenschaft
DGP) (Request no. EK-15-003).
Process evaluation
We will carry out a process evaluation to identify fac-
tors that might facilitate or interfere with the success-
ful implementation of the intervention [52, 86]. The
process evaluation contributes to a deeper under-
standing of the relation between the components of
the intervention and the intervention effectiveness or
failure. We used the guidance for process evaluation
of cluster-randomized trials by Grant et al. [87]. It in-
cludes the following process evaluation components:
trial delivery, intervention implementation and the re-
sponses of targeted participants. Following Grant et al.
[87], we distinguish between clusters and individuals
to address the specifics of a cluster-randomized trial.
Furthermore, we will consider the domains: context
of the study, applied theory and unintended conse-
quences (see Additional file 2).
The objectives of our process evaluation are as follows:
1. describe our recruitment strategy and to identify
reasons for participation and non-participation
(clusters and individuals), so that a conclusion about
the generalizability of the study results and
implementation conditions can be made.
2. ensure that the training intervention (SPUPEO-
workshop and training, SPUPEO is a German
acronym “Spezialisierte Pflegefachkräfte zur
Unterstützung einer informierten partizipativen
Entscheidungsfindung in der Onkologie,” which
means “qualified nurses to support SDM in
oncology”) was delivered as intended because
variations in intervention delivery might cause
outcome differences between the clusters.
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3. gather the attitude of health care professionals
about decision coaching as an indicator for the
response of clusters.
4. ensure that the decision coaching was delivered as
intended (intervention fidelity) since variations in
intervention delivery might cause outcome
differences between the patients.
5. gather the attitude of patients about decision coaching
and patient participation since it is associated with the
acceptance of the intervention and the outcomes.
6. identify which intervention components work,
which do not and why.
7. look for unintended consequences of the intervention.
8. identify differences between the clusters that might
influence the effectiveness of our intervention.
9. identify structural barriers and facilitators of a
successful implementation of decision coaching into
the breast care center.
We chose an explanatory mixed-methods design to
get a better conception of (inter-) dependencies and re-
lated factors that influence function and outcome of the
complex intervention [88, 89].
After study completion, we will conduct telephone in-
terviews with involved physicians and nurses. The inter-
view will focus on potential barriers and facilitators that
are revealed from the study results and previous results
of the process evaluation.
Discussion
The study aims at the evaluation of a structure changing
complex intervention to improve informed SDM in breast
care centers. As yet, decision coaches have not been imple-
mented in standard care in oncology in the German health-
care system. An environmental scan of Légaré et al. [90]
reveals that inter-professional approaches of shared deci-
sion-making are lacking. The intervention has advan-
tages such as the low-threshold offer for patients and
continuity of care. The strength of the study is that
our outcome focuses on the mutual SDM behavior of
all involved parties. However, we could not take into
account the perceived SDM behavior of the involved
parties in our primary outcome, since no validated
compound measure for inter-professional SDM exists.
Our primary endpoint assesses the extent of SDM of
the whole decision-making processes. Each process is
based on two talks in the IG and one talk in the CG due
to our structural intervention. Talking with two health
care professionals may result in higher overall SDM per-
formance. Hence, systematic differences in this outcome
are possible. In the IG, the decision-making process is
split. In this respect, focusing only one talk would skip
part of the whole process. Applying one holistic meas-
urement for the process in the IG will meet this doubt.
In addition, using MAPPIN’SDM for decision-making
processes comprising two talks has not been validated yet.
To estimate construct validity, interrater reliabilities will
be computed and the consensus ratings of two independ-
ent raters will be used to calculate the primary endpoint.
The study has limitations, since blinding of clusters,
women and assessors is not possible. Since the allocation
of women is not concealed, a selection or participation
bias may occur.
The potential selection bias of participating women is
challenging. Physicians might not ask every eligible
woman, because of implicit assumptions of eligibility for
example, age or educational background. This issue will
be discussed with all participating physicians. The number
of eligible women will be monitored in all centers. In
addition, strategies to speak to eligible women will be dis-
cussed and a guideline for physicians will be provided.
One further limitation is that some breast care centers
already involve specialized nurses in counselling of women
prior to the treatment decision. Because we only focus on
the physician consultation in the control group, we might
overlook the SDM behavior of nurses that would lead to
an improvement of the extent of SDM in the control
group. We will record if nurses are part of the usual coun-
selling process prior to randomization, but the extent and
quality of possible nurse counselling regarding SDM will
not be quantified. Within the scope of process evaluation,
we video tape these nurse encounters, too.
The video recordings might influence healthcare pro-
fessionals due to the artificial situation. However, this
effect might occur in both groups.
The cluster design has been chosen to avoid contam-
ination between study arms. However, breast care nurses
are organized in networks and might exchange informa-
tion about the study intervention.
We defined seeking a second opinion as exclusion cri-
terion. Women might have already been included in the
study in the center they visited first and should not be
asked for participation a second time.
In summary, the results will indicate if decision coa-
ches will improve informed shared decision-making in
oncology and which resources and conditions are neces-
sary to implement the new model in certified breast care
centers in Germany.
Protocol amendments
Modifications or amendments that have an impact on
the conduct of the study will be documented and un-
veiled in further publications.
Confidentiality
All members of the research team will practice profes-
sional secrecy. We will comply with the federal states’ data
protection laws. To ensure data privacy, pseudonyms are
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used that allow combining data sets and deleting of data if
patients withdraw informed consent. The pseudonym list
and informed consent forms are kept under lock at the
participating study centers. Computer files are code-
locked to prohibit unauthorized access. Anonymization of
the video-material is not possible. Data that give hints to
identification of individuals will not be assessed. Videos
will be deleted after study completion. Anonymity of par-
ticipants will be observed strictly within the publications.
Access to data
The study center will coordinate the intra-study data
sharing process. The cleaned data sets will be available
for all principal investigators. In order to meet the re-
quirements of the data sharing policy for clinical trials of
the Institute of Medicine [91, 92], full access to raw data
will be available on request.
Dissemination policy
Results will be published in scientific journals. According
to the recommendations of the International Committee
of Medical Journal Editors (ICMJE), only persons directly
involved in the study will be designated as authors [93].
Trial status
Currently, the recruitment of breast care centers is on-
going. Patients will be recruited from July 2015 until
March 2016.
Additional files
Additional file 1: Completed SPIRIT checklist. (DOCX 61 kb)
Additional file 2: Domains of process evaluation and objectives.
(DOCX 19 kb)
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